Objective To investigate the prevalence of human bocavirus(HBoV)among children with acute respiratory tract infection(ARTI)in Guangdong Province.Methods Four hundred and forty-seven nasopharyngeal aspirates or swabs samples from children with ARTI in Guangdong Province were collected from June 2007 to May 2008.HBoV capsid protein VP gene fragments were detected using polymerase chain reaction(PCR).Positive PCR products were sequenced.The DNA and translated amino acid sequences were aligned with known HBoV sequences in GenBank and phylogenetic analysis was also done.Results The positive rate of HBOV was 5.1%of samples from 447 ARTI cases.Ten samples were positive for both HBoV and other respiratory virus,which was 43.5%of positive samples.The main diagnosis for HBoV positive children included wheezing pneumonia,bronchiolitis and bronchial pneumonia.HBoV positive children ranged from 42 days to 6 years old,and most of them were younger than one year.HBOV infection was more common during summer,early autumn and late spring.Through sequence alignment and phylogenetie analysis,the DNA sequences and amino acid sequences of VP gene fragments of isolated HBoV strains showed 97.8%-98.8%and 99.3%-100.0%identity with ST1,respectively.Conclusions HBoV is one of the important pathogens of lower respiratory tract infection in children in Guangdong Province,which is more prevalent in infants younger than one year.Although VP gene fragment of HBoV is conservative in general,there are still some missense mutations.

Objective To obtain the peptide mass fingerprintings(PMF)of serums of the patients with bone metastasis and with-out metastasis and to filtrate and identify the differential serum proteins of patients with bone metastasis after radical mastectomy . To establish diagnostic models for diagnosis of bone metastasis after breast cancer operation .Methods Two groups of serum sam-ples were analyzed by ClinprotTM MALDI-TOF MS and gain PMF ,18 samples from patients with merely bone metastasis and 18 samples from patients without metastasis .Characteristic protein peaks were analyzed and selected by analyses software within Clin-prot system .Every group was repeated 2 times .Results All serum samples were repeated after 5 days and the fingerprintings were similar to the former .4 protein peaks were selected randomly to compute coefficient of variation which are less than 30% .The Clin-prot system has excellent repeatability .No differential protein was detected by analyzing PMF (P>0 .05) .Conclusion No differen-tial serum protein exists in patients with bone metastasis and without metastasis and detecting differential protein in peripheral blood may be impossible .

Objective To study the patient movements features during radiotherapy . Methods Randomly selected 120 patients treated in our hospital from February to July on 2016,including 60 thorax treatment and 60 abdomen treatment. The movement data of patient treatment location during radiotherapy treatment was real time monitored by using Sentinel system,movement features of patient′s location during radiotherapy was analyzed. Paired t-test difference. Results During radiotherapy,patient′s treatment location movement types and proportion were motionless type 14. 0%,Moving stable type 64. 0%,Jumping type 8. 7%,increasing type 13. 3%.Patients with thoracic and abdominal radiotherapy,the maximum deviation of IMRT and VMAT treatment were (6.55±2. 34) mm and (4.97±1. 24) mm (P = 0. 002),(3.97±1. 80) mm and (2.69± 1. 42) mm (P = 0. 004).In single treatment,the deviation value of the patient′s treatment location increased gradually with the treatment time increasing and the deviant of thoracic is greater than abdominal at the same time after the treatment beginning. Conclusions Patient′s treatment location movement during radiotherapy is commonly exist,using the technology of VMAT treatment can effectively reduce the treatment site movement of the patient during the treatment and ensure the accuracy of dose.

EIDD-2801 is an orally bioavailable prodrug, which will be applied for emergency use authorization from the U.S. Food and Drug Administration for the treatment of COVID-19. To investigate the optimal parameters, EIDD-2801 was optimized